India Bans Multiple Irrational Fixed Dose Combination Drugs: Key Compliance Updates for the Pharmaceutical Industry

On 11th June 2026, the Ministry of Health and Family Welfare banned the manufacture, sale, and distribution of 16 fixed-dose combination (FDC) drugs across India. This fixed dose combination drug ban 2026 was issued through 16 separate notifications under Section 26A of the Drugs and Cosmetics Act, 1940, and published in the Gazette of India on 15th June 2026.

If your business produces, markets, imports, or distributes any medicine in India, then this news update affects you. A prohibition order is not issued regularly. This means that the production, sale, and distribution of such combinations after the date of issuance of the notice becomes illegal.

This article aims to provide simple information about the changes, the government's rationale for the decision, the combination involved, and the actions to be taken by pharma manufacturers, formulators, distributors, and retailers. The guidance becomes more complex when reformulation, stock reduction, or other regulatory issues are involved; therefore, it is necessary to consult a professional at Corpseed in such cases.

Key Highlights

• The Central Government has prohibited the manufacture, sale, and distribution of 16 fixed-dose combination (FDC) drugs for human use, with immediate effect.
• The ban was issued through notifications S.O. 3068(E) to S.O. 3083(E), dated 11th June 2026, published in the Gazette of India on 15th June 2026.
• The legal basis is Section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), which empowers the Central Government to prohibit a drug when it is satisfied that its use poses a risk to human beings and safer alternatives exist.
• The banned list includes well-known combinations involving Amoxicillin, Cefadroxyl, Cefuroxime, Dicyclomine, Paracetamol, Gliclazide, as well as several Aloe Vera- and herbal-based fixed-dose combinations.
• Every combination was first flagged by an Expert Committee in 2021, which found them "irrational" for lacking supporting scientific and peer-reviewed evidence.
• The Drugs Technical Advisory Board (DTAB) examined the Expert Committee's findings and, in principle, agreed with the recommendation.
• A Sub-Committee of DTAB was formed to examine each combination in detail and allowed manufacturers and stakeholders to submit data through public notices.
• The Sub-Committee submitted its final report on 28th December 2024, recommending prohibition in the larger public interest.
• The order takes effect immediately from the date of notification there is no transition or sell-through period mentioned in the notifications.
• Businesses currently manufacturing, marketing, or holding stock of any of these 16 combinations must cease operations related to these combinations and review their regulatory position without delay.

The Regulatory Framework

Applicable Law

These notifications are made under Section 26A of the Drugs and Cosmetics Act, 1940. Section 26A grants the Central Government the authority to prohibit the manufacture, sale, or distribution of any drug if it believes the drug is likely to be hazardous to humans, there are safer alternatives available, or it is not therapeutic.

What Is a "Fixed Dose Combination" (FDC)?

A fixed-dose combination is a single pharmaceutical product that contains two or more active ingredients in a fixed dose ratio. FDCs are common because they can improve patient compliance (fewer pills to take). Still, if the ingredients lack sound scientific justification for combination, they can pose unnecessary risks without added therapeutic benefit. This is precisely the concern raised across all 16 notifications.

Scope

These prohibitions apply nationwide and cover manufacture, sale, and distribution for human use. There is no exemption carved out in the notifications for existing stock, export-only production, or specific states.

What Has Changed: The Full List of Banned FDCs

Each of the 16 notifications follows the same regulatory process but applies to a different drug combination. Here is the complete list with their notification numbers:

Previous Position vs New Position

Common Reasons Cited Across the Notifications

While each combination has its own specific finding, a few recurring reasons appear across the 16 notifications:

• No sound clinical or pharmacodynamic justification for combining certain active ingredients (for example, antibiotic combinations with enzyme preparations like Serrati peptidase, where the committee found no solid clinical evidence supporting concurrent use).
• Lack of peer-reviewed scientific evidence supporting the rationality of the combination.
• Deviation from standard treatment guidelines, both national and international (as seen in the Gliclazide + Chromium Picolinate combination, where standard Type 2 Diabetes treatment guidelines do not recommend Chromium Picolinate).
• Undefined or uncharacterized products, particularly among several Aloe vera and herbal-based topical combinations, where the committee noted the product itself was not well defined.
• Absence of pharmacokinetic data to justify dose combinations, as seen in the Cefadroxyl + Probenecid notification.
• Risk exceeding benefit in the larger public interest, even where individual ingredients may be safe on their own.

Implementation Timeline / Norms

Effective Date

All 16 notifications state that the prohibition applies "with immediate effect" from the date of the notification, i.e., 11th June 2026.

No Stated Transition Period

Unlike some regulatory changes that allow a grace period to liquidate existing stock or transition to alternate formulations, these notifications do not mention any sell-through or transition window. This makes immediate compliance review critical.

Regulatory Process Timeline (For Context)

Understanding how this ban evolved can help businesses anticipate future FDC reviews:

• 2021: Expert Committee examines each FDC and finds them "irrational."
• Post-2021: DTAB reviews the Expert Committee's findings and agrees in principle.
• DTAB Sub-Committee formed: tasked with detailed examination of all irrational FDCs.
• Public notices issued: Manufacturers and stakeholders allowed to submit precise data defending the combination.
• 28th December 2024: Sub-Committee submits its final report recommending prohibition.
• DTAB agrees with the Sub-Committee's recommendation.
• 11th June 2026: Central Government issues the final prohibition notifications under Section 26A.

This roughly five-year process shows that FDC reviews in India move through multiple layers of expert scrutiny before a ban is finalised, which also means businesses holding FDC licences should track ongoing DTAB reviews proactively rather than waiting for a final notification.

Why Was This Implemented?

The government's stated objective across all 16 notifications is consistent: protecting public health by removing drug combinations that carry risk without adequate therapeutic justification, especially where safer alternatives already exist.

Key objectives include:

• Patient safety: removing combinations where the risk-benefit balance does not favour the patient.
• Scientific rigour in drug approval: ensuring that combination drugs are backed by real clinical evidence, not just commercial convenience.
• Rational use of medicines: aligning with India's broader effort (going back to earlier FDC bans in 2016 and subsequent years) to clean up the market of combinations that lack a sound pharmacological basis.
• Alignment with standard treatment guidelines: as seen with the Gliclazide + Chromium Picolinate case, where the combination did not match national or international treatment protocols.
• Preventing irrational polypharmacy: several banned combinations added ingredients (such as enzymes or vitamins) to established drugs without clear added benefit, increasing exposure to side effects unnecessarily.

Impact on Businesses

• Manufacturers: Manufacturers currently producing any of the 16 listed FDCs must immediately halt production. Continuing to manufacture a prohibited drug can expose the company to penal action under the Drugs and Cosmetics Act, including seizure of stock and cancellation of related manufacturing licences.
• Importers: If any of these combinations are imported into India in finished or bulk form, import of the prohibited combinations must stop. Import licences tied specifically to these formulations will need to be reviewed and, where applicable, surrendered or amended.
• Exporters: The notices specifically limit manufacture, sale, and distribution for human consumption in that country. Firms that export such combinations need to carefully consider whether an export manufacturing operation is feasible, since the export business remains subject to India's regulations and manufacturing laws.
• Brand Owners and Marketing Companies: Brand owners who outsource manufacturing (loan licensing/third-party manufacturing arrangements) are equally responsible for compliance. Marketing and promotional activity for these brands must stop immediately, including trade communication, MR (medical representative) detailing, and e-pharmacy listings.
• MSMEs and Startups: Smaller pharmaceutical manufacturers, often reliant on a narrower product portfolio, may feel a sharper financial impact from a sudden ban. MSMEs should prioritise a rapid compliance review to avoid inventory write-offs that could lead to legal exposure.
• Large Enterprises: Larger pharma companies with wide product portfolios should still treat this as serious regulatory non-compliance; even one SKU can trigger scrutiny of the entire manufacturing licence and facility.
• Traders, Distributors, and Retailers: Anyone holding existing stock of these 16 combinations from stockists to retail pharmacies should stop further sale and consult with their supplier or a regulatory expert on the appropriate way to handle existing inventory.
• Service Providers (Formulation Developers, CROs, CDMOs): Contract development and manufacturing organisations (CDMOs) and formulation R&D teams working on any of these combinations, or structurally similar combinations, should reassess ongoing projects in light of the reasoning given in these notifications, since similar combinations may face similar scrutiny in future DTAB reviews.

How will Businesses achieve Compliance?

The following is a compliance roadmap for businesses impacted by the notification:

Step 1: Verification of Impact

Verify whether you fall within the scope of the notification by cross-verifying your product range, active pharmaceutical ingredients used, and drug manufacturing licence (Form 25/28). Variations in the ratio or additional inclusion of ingredients may still place your business within the scope of this notification.

Step 2: Immediate Suspension of Production, Sales and Distribution

Since the ban is immediate, businesses cannot plan for a gradual closure. The manufacture, marketing material, and distribution must be stopped immediately.

Step 3: Modification of your Manufacturing Licences

Your manufacturing licence (form 25/28) might require modification, as the banned combination must be removed from the approved products under your licence.

Step 4: Disposal of existing Stock

It cannot be assumed that stock manufactured earlier is exempt from this ban. Seek advice from the State Drug Control Authority regarding proper disposal or recall procedure.

Step 5: Communication to Distribution Network

Send a communication about the ban to your distribution channel so the product is removed from sales channels.

Step 6: Review of Research Pipeline

If your research pipeline includes other combinations that have been banned, reconsider the scientific justification based on the DTAB findings before progressing further.

Step 7: Documentation

Document all compliance measures in case any scrutiny happens in the future.

Common Compliance Mistakes to Avoid

• Assuming a "grace period" exists when the notification says "immediate effect."
• Continuing to sell existing inventory without checking with the licensing authority.
• Overlooking loan-licensing or third-party manufacturing arrangements when assessing exposure.
• Failing to update marketing and e-commerce/e-pharmacy listings promptly.
• Not documenting the compliance actions taken, which can matter significantly during inspections.

If you're unsure whether your product formulation matches a banned combination exactly (for example, a similar but not identical ratio), don't self-assess. A regulatory consultant can help you interpret the notification in the context of your specific product dossier and avoid both over-compliance (unnecessarily halting a legal product) and under-compliance (continuing to market an illegal one).

Benefits for Businesses That Get Compliance Right

While a ban is disruptive, businesses that respond to it correctly and quickly stand to gain in several ways:

• Avoiding penalties and legal action under the Drugs and Cosmetics Act.
• Protecting manufacturing licences from suspension or cancellation risk tied to a single non-compliant product.
• Maintaining market and distributor trust, since a swift, professional response signals regulatory maturity.
• Freeing up R&D and manufacturing capacity to reformulate or pivot to compliant, evidence-backed alternatives.
• Reducing future regulatory risk by using this as an opportunity to review the rest of the product portfolio for similar irrational combinations.
• Smoother business continuity by acting early rather than waiting for a regulatory notice or inspection.

Right Decision or Additional Burden?

It's fair to look at this from both sides.

From a public health standpoint, the ban is a reasonable and evidence-based decision. Each of the 16 combinations underwent a multi-year review, an Expert Committee assessment, a DTAB evaluation, a dedicated Sub-Committee review, and an opportunity for manufacturers to submit data before the final prohibition. That is a considerably more thorough process than an abrupt regulatory decision.

As far as the business implications of the notification go, the lack of any phase-in period to ease the compliance process can pose practical problems: from excess stock to the need for immediate licence changes, all of which pose real obstacles.

The balanced perspective: regarding the regulatory intent behind the notification itself, it is clearly a good move to eliminate drug combinations lacking scientific evidence. However, the time frame set by the regulators poses a challenge for those businesses that operated within legal boundaries until the announcement was made.

Business Opportunities Created

A regulatory disruption like this also opens doors:

• Reformulation opportunities- Companies can develop scientifically justified alternatives to replace the banned combinations, potentially capturing market share vacated by the ban.
• Consulting demand- Pharma companies across the country will need regulatory support to interpret and act on this notification, creating opportunities for compliance consultants and legal advisors.
• Portfolio review as a competitive edge- Companies that proactively audit their full portfolio against DTAB's ongoing "irrational FDC" review process can position themselves ahead of future bans.
• Trust-building with regulators- Businesses that respond transparently and promptly to this notification build long-term credibility with licensing authorities, which can smooth future approvals.
• Export and manufacturing realignment- Companies can use this as a trigger to review and modernise their broader manufacturing and product strategy.

Why Choose Corpseed?

Navigating a sudden regulatory prohibition like this is not something to handle informally. Corpseed works with pharmaceutical manufacturers, importers, and distributors across India on:

• End-to-end regulatory compliance support for drug licensing under the Drugs and Cosmetics Act, 1940
• Manufacturing licence review, amendment, and renewal assistance
• Documentation support for stock recall, licence surrender, or product discontinuation
• Guidance on reformulation and fresh product approval pathways.
• Liaison support with State Drug Control Authorities and the Central Drugs Standard Control Organisation (CDSCO).
• Application filing for new drug approvals and licence modifications.
• Pan-India support for businesses operating across multiple states with different licensing authorities.
• Dedicated regulatory experts who track ongoing DTAB reviews so you're not caught off guard by future FDC prohibitions
• A transparent, structured process with clear timelines, so you know exactly where your compliance stands at every stage.

Whether you need to urgently amend a manufacturing licence, manage existing stock of a banned FDC, or explore compliant reformulation options, Corpseed's regulatory team can guide you through the process without unnecessary delays.

Corpseed's Core Message

Regulatory notifications like this one don't leave room for a "wait and watch" approach. The prohibition is already in effect, and the risk of continuing to manufacture, sell, or distribute any of these 16 combinations grows with every day of inaction.

If your business is affected even partially, even though a third-party manufacturing arrangement is the smartest move, it is to get a clear, expert read on your exposure before it becomes a compliance issue. Delayed action on drug prohibitions can lead to stock seizures, licence suspension, and reputational damage that takes far longer to repair than the compliance process itself.

Corpseed's regulatory consultants can help you assess your exposure, manage the transition, and get your documentation in order so you can focus on running your business. At the same time, the compliance side is handled by people who track these notifications for a living.

Talk to a Corpseed regulatory expert today to review your product portfolio against this notification and stay ahead of future FDC reviews.